Summary
Efficacy and safety of ABT-874 versus methotrexate in patients with moderate to severe psoriasis
Summary
Study of methotrexate efficacy versus cyclosporine in moderate to severe atopic dermatitis patients (METHODA)
(NCT00809172)
Summary
A double blind study in pediatric subjects with chronic plaque psoriasis, studying adalimumab vs. Methotrexate (NCT01251614)
Summary
Efficacy and safety of ABT-874 versus methotrexate in patients with moderate to severe psoriasis
Summary
Efficacy and safety of ABT-874 versus methotrexate in patients with moderate to severe psoriasis
Summary
Comparison of benefit-risk profiles for adalimumab, methotrexate, and placebo in the treatment of moderate to severe psoriasis
Summary
Adalimumab response is consistent across subgroups of patients with moderate to severe psoriasis: Subanalysis of the CHAMPION study
Summary
Adalimumab response is consistent across subgroups of patients with moderate to severe psoriasis: Subanalysis of the CHAMPION study
Summary
Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free response days in the CHAMPION trial
Summary
Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free remission days in the CHAMPION trial
This site complies with the HONcode standard for trustworthy health information: